Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
February 03 2017 - 7:00AM
Business Wire
Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome
therapeutics platform company, today announced that management will
participate in two upcoming investor conferences:
- Canaccord Genuity Rare Disease and
BioPharma 1x1 Day on Tuesday, February 7, 2017 in New York, NY
- 6th Annual Leerink Partners Global
Healthcare Conference on Wednesday, February 15, 2017 in New York,
NY; presentation at 11:00 a.m. ET
Live audio webcast of the Leerink presentation be available
under the “Investors and Media” section of Seres’ website. A replay
of the presentation will become available approximately one hour
after the event and will be archived for 21 days.
About Seres TherapeuticsSeres Therapeutics, Inc. is a
leading microbiome therapeutics platform company developing a novel
class of biological drugs that are designed to treat disease by
restoring the function of a dysbiotic microbiome, where the natural
state of bacterial diversity and function is imbalanced. The Phase
2 study of Seres' program SER-109 has been completed in multiply
recurrent C. difficile infection. Seres' second clinical
candidate, SER-287, is being evaluated in a Phase 1b study in
patients with mild-to-moderate ulcerative colitis (UC). Seres is
also developing SER-262, the first ever synthetic microbiome
therapeutic candidate, in a Phase 1b study in patients with
primary C. difficile infection. For more information,
please visit www.serestherapeutics.com. Follow us on Twitter
@SeresTx.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170203005081/en/
Seres TherapeuticsCarlo Tanzi, Ph.D., 617-203-3467Head of
Investor Relations and Corporate
CommunicationsCtanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Sep 2023 to Sep 2024